Author: Editor

Steven Horwitz, MD of @sloan_kettering discusses the phase 2 PRIMO study. _______ Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced the presentation of key abstracts highlighting COPIKTRA® (duvelisib) data at the American Society of Hematology 2019 Annual Meeting taking place December 7-10, 2019, in Orlando.   “Given the aggressive nature of peripheral T-cell lymphoma (PTCL) and the lack of effective therapeutic options for these patients, we are pleased to present data from the dose optimization phase of our…

Duvelisib Achieves Overall Response Rate of 62% in Patients with Relapsed or Refractory PTCL with Manageable Safety Profile in Initial Phase of PRIMO Trial   Data Presented Supports Potential of Duvelisib Across Indications, Lines of Therapy and in Combination   Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced the presentation of key abstracts highlighting COPIKTRA® (duvelisib) data at the American Society of Hematology 2019 Annual Meeting taking place December 7-10, 2019, in Orlando.   “Given the aggressive nature…

Aaron Gerds, MD of @CleClinicMD discusses the phase 2 study of luspatercept in patients with myelofibrosis-associated anemia

Aaron Gerds, MD of @CleClinicMD discusses the phase 2 study of luspatercept in patients with myelofibrosis-associated anemia

Fredrik Schjesvold, MD of Oslo University College addresses how this affects clinicians and what is next for research.

Fredrik Schjesvold, MD of Oslo University College disucsses the ICARIA-MM study.

Eric Fedyk, PhD of @TakedaPharma discusses the binding of CD38 therapeutics to red blood cells and platelets subverts depletion of target cells.

Eunice Wang, MD of @RoswellPark discusses cladribine, cytarabine, granulocyte colony stimulating factor ± mitoxantrone (CLAG ± M) is highly effective therapy for secondary and relapsed/refractory AML.

Shouryadeep Srivastava, MBBS, PhD of @TakedaOncology discusses CML patients prescribed ponatinib vs bosutinib: what is next for research?

Shouryadeep Srivastava, MBBS, PhD of @TakedaOncology discusses CML patients prescribed ponatinib vs bosutinib.

Dawn Marie Stull, PharmD of @TakedaOncology discusses closing the efficacy and effectiveness gap: outcomes in relapsed/refractory multiple myeloma (RRMM) patients (Pts) treated with ixazomib-lenalidomide-dexamethasone (IRd) in routine clinical practice remain comparable to the outcomes reported in the phase 3 tourmaline-MM1 study.

Dawn Marie Stull, PharmD of @TakedaOncology discusses closing the efficacy and effectiveness gap: outcomes in relapsed/refractory multiple myeloma (RRMM) patients (Pts) treated with ixazomib-lenalidomide-dexamethasone (IRd) in routine clinical practice remain comparable to the outcomes reported in the phase 3 tourmaline-MM1 study.

David Gilham, MD of Celyad discusses a human NKG2D receptor-based CAR-T cell that potentially targets 80% of all cancers.

Christopher Yasenchak, MD of @TheUSONetwork discusses the phase 2 study of frontline brentuximab vedotin plus nivolumab.

Brian Hill, MD of Cleveland Clinic @ClevelandClinic discusses KTE-X19

Baiyan Wang, MD of Hospital of Xi’an Jiaotong University discusses the LEGEND-2 data.

Nizar Bahlis, MD of University of Calgary discusses patients with newly diagnosed multiple myeloma (MM) ineligible for transplant: updated analysis of MAIA.

Alexey Danilov, MD of @OHSUNews discusses pharmacologic inhibition of SUMO-activating enzyme (SAE) with TAK-981 augments interferon signaling and regulates t cell differentiation.

– TAILORx Study Featured in William L. McGuire Memorial Lecture Award at 2019 San Antonio Breast Cancer Symposium® – New Publication of Long-term Data from Real-world Clinical Practice Confirms Conclusions of TAILORx   Exact Sciences Corp. (NASDAQ: EXAS) today announced new outcomes data from two large population-based studies1,2 presented at the 2019 San Antonio Breast Cancer Symposium (SABCS®). The real-world evidence suggests that use of the Oncotype DX Breast Recurrence Score® test in clinical practice is consistent with previous clinical validation studies including TAILORx, the largest ever breast cancer treatment trial. This landmark study was featured in the William L. McGuire Memorial Lecture Award, which recognized Joseph A.…

Jarrod Dalton, MD and David Zidar, MD of @CleClinicMD discuss lymphopenia associated with death due to heart disease, cancer and respiratory infections, including influenza and pneumonia. ___________ A new collaborative study led by Cleveland Clinic and University Hospitals has found that commonly used clinical indicators of immune status and inflammation can predict mortality in the general population. Published in JAMA Network Open, the study showed that lymphopenia (a condition characterized by low levels of a specific type of white blood cell, called lymphocytes) is associated with death due to heart disease, cancer and respiratory infections, including influenza and pneumonia. This relationship…

Agne Paner, MD of @RushMedical discusses updated data from the phase 2 HORIZON study. __________ Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present follow-up data from the pivotal Phase 2 HORIZON (OP-106) study at the ASH Annual Meeting 2019. Melflufen showed an overall response rate (ORR) of 29% and clinical benefit rate (CBR) of 37% in patients with late-stage relapsed/refractory multiple myeloma (RRMM). The safety profile remained consistent with prior reports from the HORIZON study. These data reinforce Oncopeptides’ view that melflufen can play a role in the treatment of patients with RRMM and the Company plans to submit a New Drug Application (NDA)…

Jarrod Dalton, MD and David Zidar, MD of @CleClinicMD discuss lymphopenia associated with death due to heart disease, cancer and respiratory infections, including influenza and pneumonia. ____________ A new collaborative study led by Cleveland Clinic and University Hospitals has found that commonly used clinical indicators of immune status and inflammation can predict mortality in the general population. Published in JAMA Network Open, the study showed that lymphopenia (a condition characterized by low levels of a specific type of white blood cell, called lymphocytes) is associated with death due to heart disease, cancer and respiratory infections, including influenza and pneumonia. This relationship…

Jennifer Crombie, MD of @DanaFarber discusses a phase I study of duvelisib and venetoclax in patients with relapsed or refractory CLL / SLL.

John Mascarenhas, MD of @MountSinaiNYC discusses MANIFEST, a phase 2 study of CPI-0610, a bromodomain and extraterminal domain inhibitor (BETi)

Nikhil Munshi of @DanaFarber discusses the phase I study evaluating interleukin-15 (IL-15) receptor agonist, NKTR-255 in MM and NHL.

Nektar Therapeutics (NASDAQ: NKTR) today announced three presentations at the 61st American Society of Hematology (ASH)   Annual Meeting & Exposition for its IL-15 agonist and investigational candidate, NKTR-255. Data were presented from a number of preclinical studies conducted in collaboration with researchers from the Dana Farber Cancer Institute and the Fred Hutchinson Cancer Research Center. NKTR-255 is an interleukin-15 (IL-15) receptor agonist, which is currently being evaluated in a Phase 1 clinical study in patients with multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL). NKTR-255 is designed to work by selectively targeting the IL-15 pathway to expand both natural killer…

Loui Madakamutil, PhD of Nektar Therapeutics discusses new preclinical Ddta for its IL-15 agonist, NKTR-255 at ASH 2019. ___________ Read here: https://www.oncologytube.com/video/nektar-therapeutics-announces-presentation-of-new-preclinical-data-for-its-il-15-agonist-nktr-255-at-the-american-society-of-hematology-ash-2019-annual-meeting

MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results for Kisqali plus fulvestrant, reducing the risk of death by almost 30%   Overall survival benefit for Kisqali plus fulvestrant was consistent regardless of line of therapy or response to prior endocrine treatment   Kisqali is the only CDK4/6 inhibitor to demonstrate consistently superior overall survival in two Phase III trials, proven with multiple combination partners and in two distinct patient populations   — MONALEESA-3 data published today in The New England Journal of Medicine (NEJM) shows Kisqali® (ribociclib) plus fulvestrant demonstrated a statistically significant improvement in overall…

John Seymour, PhD of @PeterMacCC discusses year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed refractory (R/R) chronic lymphocytic leukemia (CLL).

Alexander Cohen, MBBS of Guys’ and St. Thomas’ NHS Foundation Trust answers the common questions asked about the safety and effectiveness of apixaban, LMWH, and warfarin among venous thromboembolism patients with active cancer.

Alexander Cohen, MBBS of Guys’ and St. Thomas’ NHS Foundation Trust discusses the safety and effectiveness of apixaban, LMWH, and Warfarin among venous thromboembolism patients with active cancer.

Thanos Zomas, MD of @TakedaOncology on brentuximab vedotin with chemotherapy for stage 3/4 classical hodgkin lymphoma (cHL): what’s next in research and exciting news at ASH 2019

Thanos Zomas, MD of @TakedaOncology discusses brentuximab vedotin with chemotherapy for stage 3/4 classical hodgkin lymphoma (cHL): 4-year update of the echelon-1 study.

Ifeyinwa (Ify) Osunkwo, MD of @LevineCancer explains the SWAY study on sickle cell disease.

Ifeyinwa (Ify) Osunkwo, MD of @LevineCancer discusses the unmet needs in sickle cell research.

Ifeyinwa (Ify) Osunkwo, MD of @LevineCancer discusses the unmet needs in sickle cell research.

Con Tam, MD of @PeterMacCC discusses the phase 2 CAPTIVATE clinical trial in CLL.: how this will affect clinicians and treatment.

Con Tam, MD of @PeterMacCC discusses the phase 2 CAPTIVATE clinical trial in CLL.

Rajat Bannerji, MD of @RutgersCancer provides an update on Phase I REGN1979.         ash 2019, rutgers cancer, regn1979, phase I, phase I regn1979, update

Dennis Cooper, MD of @RutgersCancer provides detail on his upcoming presentation at ASH about clinical data on REGN5458

Zsuzsanna Devecseri, MD of @SanofiGenzyme @sanofi discusses the pivotal Phase 3 ICARIA-MM trial of isatuximab, an investigational anti-CD38 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM) presented at the ASH.

Deepu Madduri, MD @DMadduri of @MountSinaiNYC @IcahnMountSinai discusses the CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against b-cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (R/R MM). Patients with multiple myeloma who had received a median of five prior therapies, and for whom standard-of-care treatments were no longer working, had a high response rate when treated with the investigational CAR T-cell therapy JNJ-4528, which targets BCMA, an antigen a protein commonly found on the surface of multiple myeloma cancer cells. Researchers said that JNJ-4528 is a novel CAR T-cell therapy featuring…

Deepu Madduri, MD @DMadduri of @MountSinaiNYC @IcahnMountSinai discusses the CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against b-cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (R/R MM). Patients with multiple myeloma who had received a median of five prior therapies, and for whom standard-of-care treatments were no longer working, had a high response rate when treated with the investigational CAR T-cell therapy JNJ-4528, which targets BCMA, an antigen a protein commonly found on the surface of multiple myeloma cancer cells. Researchers said that JNJ-4528 is a novel CAR T-cell therapy featuring…

Mark Sellmyer, MD, PhD @sellmyerlab of @PennMedicine explains how CAR-T cell imaging markers will affect treatment and clinicians. ___________ Read here: https://www.eurekalert.org/pub_releases/2019-11/uops-tmc110519.php

Mark Sellmyer, Md, PhD @sellmyerlab of @PennMedicine answers how sensitive is this technology? ___________ Read here: https://www.eurekalert.org/pub_releases/2019-11/uops-tmc110519.php

Mark Sellmyer, MD, PhD sellmyerlab of @PennMedicine discusses to monitor cancer therapy, researchers tag CAR-T cells with imaging markers. ___________ Read here: https://www.eurekalert.org/pub_releases/2019-11/uops-tmc110519.php

Dr. Susan Branford

Dr. Jorge Cortez

American doctor and cancer research scientist, Dr. William G. Kaelin, Jr. (Harvard University and Dana Farber Cancer Institute), along with 2 colleagues, Sir Peter Ratcliffe (University of Oxford, United Kingdom) and Dr. Gregg Semenza (Johns Hopkins University) have been selected as the 2019 Nobel Prize in Medicine recipients for their discoveries of how cells sense and adapt to oxygen availability. This work has been completed through the understanding of the von Hippel-Lindau (VHL) gene and is enabling better understanding of abnormal cell or cancer growth. “The work of these three men, and particularly Dr. Kaelin, who has focused on the…

Dr. Ekaterina Chelsheva